This inventor holds 2 USPTO granted patents and 1 published patent application and 2 EPO patents. Top assignees: Alnylam Pharmaceuticals, Inc., Imperial College of Science, Technology and Medicine. Active years: 2011-2015.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
2 out of 466 
1 out of 112 
Years Active: 2011-2015
Title: Innovative Mind: The Patented Work of Elizabeth Louise Hardaker
Introduction
Elizabeth Louise Hardaker, a notable inventor based in London, GB, has made significant contributions to the field of biotechnology. With two patents to her name, she is recognized for her innovative solutions aimed at addressing critical health issues related to gene expression.
Latest Patents
Hardaker's latest inventions focus on compositions and methods for inhibiting the expression of the IKK-B gene. Her first patent involves a double-stranded ribonucleic acid (dsRNA) that inhibits this gene's expression. The dsRNA features an antisense strand with a nucleotide sequence less than 30 nucleotides in length, typically ranging from 19-25 nucleotides. This strand is substantially complementary to at least a portion of the IKK-B gene. Moreover, the invention includes a pharmaceutical composition composed of dsRNA and a pharmaceutically acceptable carrier. She also outlines methods for treating diseases caused by the expression or activation of the IKK-B gene using her pharmaceutical composition, as well as methods for inhibiting its expression in a cell.
Career Highlights
Throughout her career, Elizabeth Hardaker has been associated with reputable organizations, including Alnylam Pharmaceuticals, Inc. and Imperial College of Science, Technology and Medicine. These institutions have provided her with platforms to refine her innovative ideas and contribute to cutting-edge biotechnological advancements.
Collaborations
Hardaker's journey in research and innovation has also seen her collaborate with notable colleagues, including Antonin de Fougerolles and Andrew Sprague. These partnerships have undoubtedly enriched her work, fostering an environment of creativity and shared expertise.
Conclusion
Elizabeth Louise Hardaker exemplifies the spirit of innovation in the biotechnology sector through her impactful patents and collaborative spirit. Her work, especially in the realm of gene expression inhibition, continues to pave the way for potential treatments for diseases, showcasing her dedication to scientific advancement and public health.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile